What CorriXR Therapeutics does

CorriXR Therapeutics is a privately held, preclinical biotechnology company developing CRISPR/Cas-based gene editing therapies for solid tumor oncology, with a primary focus on lung, head & neck, and esophageal squamous cell carcinomas. The company's lead asset, CXR101, uses a proprietary CRISPR-based approach to disable NRF2 — a transcription factor chronically hyperactive in squamous tumors that drives survival, treatment resistance, immune evasion, and metabolic reprogramming — by delivering the editing machinery directly to the tumor site via ionizable lipid nanoparticles (LNPs). This localized delivery architecture is designed to concentrate therapeutic activity in the tumor while limiting systemic exposure relative to conventional chemotherapy and radiation. Preclinical studies published in 2025 demonstrated that editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects, and the company has received positive FDA feedback ahead of a planned first-in-human trial. CorriXR also has a collaboration with InhaTarget Therapeutics (Belgium) and Merxin Ltd (UK) to develop an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, extending the platform beyond intratumoral LNP administration.

The company was founded in 2022 as a spinout of the ChristianaCare Gene Editing Institute, where founder and Chief Scientific Officer Eric B. Kmiec, Ph.D. leads the underlying research program alongside 35+ years of gene editing experience, 165 peer-reviewed publications, and 15 issued patents. CorriXR is headquartered in Newark, Delaware, employs 11-50 people, and is led by CEO Hilary M. Malone, Ph.D. (formerly Chief Regulatory Officer at Sanofi and COO at Valo Health) and COO Jan Case (formerly of Spark Therapeutics, where she supported the Luxturna FDA approval). Capital sources to date include a 2022 founding round of approximately $6.5M from ChristianaCare Health Systems and Brookhaven Bio, two $1M grants from the State of Delaware (2023 and 2025), a January 2024 seed investment from Cortado Ventures, and an exempt securities offering of more than $8M in early 2024.

CorriXR is pre-revenue and pre-commercial; all current activity is directed at advancing CXR101 through IND-enabling studies, regulatory submissions, and first-in-human clinical execution. The company has no approved product, no disclosed pricing, and no active distribution channels. Future revenue mechanics are described as licensing/royalties, contingent on successful clinical development and regulatory approval. As such, the business is currently financed entirely through private capital and state grants, with the go-to-market motion channeled through scientific publication, conference presentation, clinical advisor networks, and institutional partnerships rather than conventional demand generation.

Name

CorriXR Therapeutics

Legal name

CorriXR Therapeutics, Inc.

Website

https://corrixr.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

CorriXR Therapeutics is a preclinical, privately held biotechnology company developing CRISPR/Cas gene editing therapies — led by candidate CXR101 — that disable NRF2 in lung, head & neck, and esophageal squamous cell carcinomas, delivered via lipid nanoparticles to overcome chemotherapy resistance.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• CRISPR gene therapy
• Oncology therapeutics
• Squamous cell carcinoma
• Gene editing platform
• Targeted genetic medicine

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-commercial / Pipeline Development: CorriXR is a pre-revenue biotherapeutics company. All current activity is focused on advancing CXR101 through preclinical development, IND submission, and into first-in-human clinical trials. Revenue generation is contingent on successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels4 records

Core offering

CorriXR Therapeutics is developing CXR101, a targeted CRISPR/Cas-based genetic medicine that disables the NRF2 transcription factor in squamous cell carcinomas of the lung, head & neck, and esophagus. The therapy uses ionizable lipid nanoparticles (LNPs) to deliver the gene-editing payload directly to the tumor site, aiming to restore chemosensitivity and limit systemic toxicity. The company is pre-commercial and advancing the program through preclinical studies toward first-in-human clinical trials.

Product overview

CorriXR Therapeutics is developing targeted genetic medicine therapies for oncology. The company's lead product is CXR101, a CRISPR-based gene editing therapy targeting NRF2 for the treatment of squamous cell cancers. The company is also developing an inhaled CRISPR gene-editing therapy in collaboration with InhaTarget Therapeutics and Merxin Ltd for squamous cell lung carcinoma.

Differentiator

Problem solved

Functional benefit

Products and services

• CXR101 CXR101 is CorriXR's lead therapeutic candidate — a CRISPR/Cas-based gene editing therapy designed to disable the NRF2 transcription factor in lung, head & neck, and esophageal squamous cell carcinomas. It is delivered directly to the tumor site via ionizable lipid nanoparticles (LNPs), with the goal of restoring chemosensitivity and limiting systemic toxicity in patients with treatment-resistant solid tumors.

Quantifiable outcome

• Editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects in preclinical studies

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• InhaTarget TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2025Belgium-based InhaTarget Therapeutics is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma. The collaboration represents a core strategic partnership focused on inhalation delivery of the company's gene editing platform.
• Merxin LtdflagshipStrategic or Co-development Partner · 1 January 2025UK-based Merxin Ltd is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, working alongside InhaTarget Therapeutics. The partnership extends the company's delivery platform capabilities for inhaled genetic medicine.
• ChristianaCare Gene Editing InstitutecoreStrategic or Co-development PartnerCorriXR emerged directly from pioneering gene editing research at the ChristianaCare Gene Editing Institute (GEI), one of the nation's leading centers for translational genetic medicine. GEI serves as the company's primary R&D engine, providing PDX and PDC mouse model validation, in vitro and in vivo studies, cell model development, and next-generation sequencing capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Prime Medicine: Clinical-stage company developing prime editing, a search-and-replace gene editing technology, for genetic diseases and oncology. Comparable to CorriXR as a next-generation gene editing platform pursuing therapeutics in oncology, though at an earlier stage of clinical translation.
• Verve Therapeutics: Clinical-stage company developing in vivo gene editing therapies using base editing and LNP delivery for cardiovascular disease. Highly comparable to CorriXR on in vivo gene editing modality and LNP delivery, though focused on cardiovascular indications rather than oncology.
• Tessera Therapeutics: Preclinical-stage company developing 'gene writing' technology — a novel platform for writing therapeutic messages into the genome. Comparable to CorriXR as a next-generation gene medicine platform pursuing in vivo therapies, though with a different underlying writing modality than CRISPR knockout.

Direct peers

• Editas Medicine: Clinical-stage gene editing company using CRISPR/Cas9 and CRISPR/Cas12a for both in vivo and ex vivo therapies targeting rare genetic diseases and oncology. Directly comparable to CorriXR in CRISPR platform and therapeutic ambition, with multiple clinical-stage assets.
• Caribou Biosciences: Clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies for hematologic malignancies. Directly comparable to CorriXR in CRISPR platform technology, with oncology focus, though differentiated by ex vivo cell therapy versus in vivo gene editing.
• CRISPR Therapeutics: Clinical-stage CRISPR/Cas9-based gene editing company developing in vivo and ex vivo gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Most directly comparable to CorriXR as both use CRISPR/Cas platforms to develop in vivo gene-editing therapeutics, with overlapping delivery technologies (LNPs).
• Intellia Therapeutics: Clinical-stage company developing in vivo CRISPR/Cas9-based gene editing therapies using LNP delivery for genetic diseases and oncology. Highly comparable to CorriXR on platform technology (CRISPR/Cas) and delivery modality (LNPs), and a direct competitor for gene editing talent and partnerships.
• Excision BioTherapeutics: Clinical-stage CRISPR-based gene therapy company developing therapies for infectious diseases. Directly comparable to CorriXR on CRISPR gene therapy platform; notable that CorriXR's CMC leader Panos Argiras was previously Senior Director of CMC Manufacturing for CRISPR-based Gene Therapy at Excision, indicating talent flow overlap.
• Beam Therapeutics: Clinical-stage precision genetic medicines company using base editing — a CRISPR-derived technology — for genetic diseases and oncology. Closely comparable to CorriXR as a next-generation gene editing platform developing precision therapeutics, including programs with LNP delivery.

Broad incumbents

• Sangamo Therapeutics: Clinical-stage genomic medicine company using zinc finger nucleases (ZFNs) for in vivo and ex vivo gene editing therapies across multiple indications. Comparable as a broad gene editing platform company with clinical-stage assets, though using a non-CRISPR nuclease platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/corrixrtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorriXR Therapeutics